Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006.

Hamid O, Robert C, Ribas A, Hodi FS, Walpole E, Daud A, Arance AS, Brown E, Hoeller C, Mortier L, Schachter J, Long J, Ebbinghaus S, Ibrahim N, Butler M.

Br J Cancer. 2018 Sep 11. doi: 10.1038/s41416-018-0207-6. [Epub ahead of print]

PMID:
30202085
2.

On the incorporation of iron into hexagonal barium titanate (I) electron paramagnetic resonance (EPR) study.

Boettcher R, Langhammer HT, Kücker S, Eisenschmidt C, Ebbinghaus SG.

J Phys Condens Matter. 2018 Sep 4. doi: 10.1088/1361-648X/aadea8. [Epub ahead of print]

PMID:
30178757
3.

Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial.

Carlino MS, Long GV, Schadendorf D, Robert C, Ribas A, Richtig E, Nyakas M, Caglevic C, Tarhini A, Blank C, Hoeller C, Bar-Sela G, Barrow C, Wolter P, Zhou H, Emancipator K, Jensen EH, Ebbinghaus S, Ibrahim N, Daud A.

Eur J Cancer. 2018 Sep;101:236-243. doi: 10.1016/j.ejca.2018.06.034. Epub 2018 Aug 7.

4.

Protein folding and quinary interactions: creating cellular organisation through functional disorder.

Ribeiro S, Ebbinghaus S, Marcos JC.

FEBS Lett. 2018 Sep;592(18):3040-3053. doi: 10.1002/1873-3468.13211. Epub 2018 Aug 24.

PMID:
30070686
5.

Pembrolizumab exposure-response assessments challenged by association of cancer cachexia and catabolic clearance.

Turner D, Kondic AG, Anderson KM, Robinson A, Garon EB, Riess JW, Jain L, Mayawala K, Kang J, Ebbinghaus SW, Sinha V, de Alwis DP, Stone JA.

Clin Cancer Res. 2018 Jun 11. pii: clincanres.0415.2018. doi: 10.1158/1078-0432.CCR-18-0415. [Epub ahead of print]

PMID:
29891725
6.

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.

Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A, Sarker D, Verset G, Chan SL, Knox J, Daniele B, Webber AL, Ebbinghaus SW, Ma J, Siegel AB, Cheng AL, Kudo M; KEYNOTE-224 investigators.

Lancet Oncol. 2018 Jul;19(7):940-952. doi: 10.1016/S1470-2045(18)30351-6. Epub 2018 Jun 3. Erratum in: Lancet Oncol. 2018 Sep;19(9):e440.

PMID:
29875066
7.

Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab.

Joseph RW, Elassaiss-Schaap J, Kefford R, Hwu WJ, Wolchok JD, Joshua AM, Ribas A, Hodi FS, Hamid O, Robert C, Daud A, Dronca R, Hersey P, Weber JS, Patnaik A, de Alwis DP, Perrone A, Zhang J, Kang SP, Ebbinghaus S, Anderson KM, Gangadhar TC.

Clin Cancer Res. 2018 Apr 23. doi: 10.1158/1078-0432.CCR-17-2386. [Epub ahead of print]

PMID:
29685882
8.

A biosensor-based framework to measure latent proteostasis capacity.

Wood RJ, Ormsby AR, Radwan M, Cox D, Sharma A, Vöpel T, Ebbinghaus S, Oliveberg M, Reid GE, Dickson A, Hatters DM.

Nat Commun. 2018 Jan 18;9(1):287. doi: 10.1038/s41467-017-02562-5.

9.

Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.

Robert C, Ribas A, Hamid O, Daud A, Wolchok JD, Joshua AM, Hwu WJ, Weber JS, Gangadhar TC, Joseph RW, Dronca R, Patnaik A, Zarour H, Kefford R, Hersey P, Zhang J, Anderson J, Diede SJ, Ebbinghaus S, Hodi FS.

J Clin Oncol. 2018 Jun 10;36(17):1668-1674. doi: 10.1200/JCO.2017.75.6270. Epub 2017 Dec 28.

PMID:
29283791
10.

Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices.

Cowey CL, Liu FX, Black-Shinn J, Stevinson K, Boyd M, Frytak JR, Ebbinghaus SW.

J Immunother. 2018 Feb/Mar;41(2):86-95. doi: 10.1097/CJI.0000000000000204.

11.

A Multiperspective Approach to Solvent Regulation of Enzymatic Activity: HMG-CoA Reductase.

Dirkmann M, Iglesias-Fernández J, Muñoz V, Sokkar P, Rumancev C, von Gundlach A, Krenczyk O, Vöpel T, Nowack J, Schroer MA, Ebbinghaus S, Herrmann C, Rosenhahn A, Sanchez-Garcia E, Schulz F.

Chembiochem. 2018 Jan 18;19(2):153-158. doi: 10.1002/cbic.201700596. Epub 2017 Dec 21.

PMID:
29139594
12.

Patient and Oncology Nurse Preferences for the Treatment Options in Advanced Melanoma: A Discrete Choice Experiment.

Liu FX, Witt EA, Ebbinghaus S, DiBonaventura Beyer G, Basurto E, Joseph RW.

Cancer Nurs. 2017 Oct 25. doi: 10.1097/NCC.0000000000000557. [Epub ahead of print]

PMID:
29076867
13.

Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program.

Gangadhar TC, Hwu WJ, Postow MA, Hamid O, Daud A, Dronca R, Joseph R, O'Day SJ, Hodi FS, Pavlick AC, Kluger H, Oxborough RP, Yang A, Gazdoiu M, Kush DA, Ebbinghaus S, Salama AKS.

J Immunother. 2017 Nov/Dec;40(9):334-340. doi: 10.1097/CJI.0000000000000186.

14.

Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.

Hamid O, Puzanov I, Dummer R, Schachter J, Daud A, Schadendorf D, Blank C, Cranmer LD, Robert C, Pavlick AC, Gonzalez R, Hodi FS, Ascierto PA, Salama AKS, Margolin KA, Gangadhar TC, Wei Z, Ebbinghaus S, Ibrahim N, Ribas A.

Eur J Cancer. 2017 Nov;86:37-45. doi: 10.1016/j.ejca.2017.07.022.

PMID:
28961465
15.

Imperfect crowding adaptation of mammalian cells towards osmotic stress and its modulation by osmolytes.

Gnutt D, Brylski O, Edengeiser E, Havenith M, Ebbinghaus S.

Mol Biosyst. 2017 Oct 24;13(11):2218-2221. doi: 10.1039/c7mb00432j.

PMID:
28929156
16.

Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment.

Liu FX, Witt EA, Ebbinghaus S, DiBonaventura Beyer G, Shinde R, Basurto E, Joseph RW.

Patient Prefer Adherence. 2017 Aug 14;11:1389-1399. doi: 10.2147/PPA.S140226. eCollection 2017.

17.

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).

Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank C, Petrella TM, Hamid O, Zhou H, Ebbinghaus S, Ibrahim N, Robert C.

Lancet. 2017 Oct 21;390(10105):1853-1862. doi: 10.1016/S0140-6736(17)31601-X. Epub 2017 Aug 16.

PMID:
28822576
18.

Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.

Long GV, Atkinson V, Cebon JS, Jameson MB, Fitzharris BM, McNeil CM, Hill AG, Ribas A, Atkins MB, Thompson JA, Hwu WJ, Hodi FS, Menzies AM, Guminski AD, Kefford R, Kong BY, Tamjid B, Srivastava A, Lomax AJ, Islam M, Shu X, Ebbinghaus S, Ibrahim N, Carlino MS.

Lancet Oncol. 2017 Sep;18(9):1202-1210. doi: 10.1016/S1470-2045(17)30428-X. Epub 2017 Jul 17.

PMID:
28729151
19.

Elucidation of the Catalytic Mechanism of a Miniature Zinc Finger Hydrolase.

Ganguly A, Luong TQ, Brylski O, Dirkmann M, Möller D, Ebbinghaus S, Schulz F, Winter R, Sanchez-Garcia E, Thiel W.

J Phys Chem B. 2017 Jul 6;121(26):6390-6398. doi: 10.1021/acs.jpcb.7b05027. Epub 2017 Jun 24.

PMID:
28648071
20.

Inhibition of Huntingtin Exon-1 Aggregation by the Molecular Tweezer CLR01.

Vöpel T, Bravo-Rodriguez K, Mittal S, Vachharajani S, Gnutt D, Sharma A, Steinhof A, Fatoba O, Ellrichmann G, Nshanian M, Heid C, Loo JA, Klärner FG, Schrader T, Bitan G, Wanker EE, Ebbinghaus S, Sanchez-Garcia E.

J Am Chem Soc. 2017 Apr 26;139(16):5640-5643. doi: 10.1021/jacs.6b11039. Epub 2017 Apr 13.

21.

A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer.

Baselga J, Morales SM, Awada A, Blum JL, Tan AR, Ewertz M, Cortes J, Moy B, Ruddy KJ, Haddad T, Ciruelos EM, Vuylsteke P, Ebbinghaus S, Im E, Eaton L, Pathiraja K, Gause C, Mauro D, Jones MB, Rugo HS.

Breast Cancer Res Treat. 2017 Jun;163(3):535-544. doi: 10.1007/s10549-017-4199-3. Epub 2017 Mar 21.

22.

Conformational dynamics and self-association of intrinsically disordered Huntingtin exon 1 in cells.

Büning S, Sharma A, Vachharajani S, Newcombe E, Ormsby A, Gao M, Gnutt D, Vöpel T, Hatters DM, Ebbinghaus S.

Phys Chem Chem Phys. 2017 May 3;19(17):10738-10747. doi: 10.1039/c6cp08167c.

PMID:
28094373
23.

Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.

Daud AI, Wolchok JD, Robert C, Hwu WJ, Weber JS, Ribas A, Hodi FS, Joshua AM, Kefford R, Hersey P, Joseph R, Gangadhar TC, Dronca R, Patnaik A, Zarour H, Roach C, Toland G, Lunceford JK, Li XN, Emancipator K, Dolled-Filhart M, Kang SP, Ebbinghaus S, Hamid O.

J Clin Oncol. 2016 Dec;34(34):4102-4109. Epub 2016 Oct 31.

24.

The temperature dependence of the Hofmeister series: thermodynamic fingerprints of cosolute-protein interactions.

Senske M, Constantinescu-Aruxandei D, Havenith M, Herrmann C, Weingärtner H, Ebbinghaus S.

Phys Chem Chem Phys. 2016 Nov 2;18(43):29698-29708.

PMID:
27806138
25.

Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma.

Schadendorf D, Dummer R, Hauschild A, Robert C, Hamid O, Daud A, van den Eertwegh A, Cranmer L, O'Day S, Puzanov I, Schachter J, Blank C, Salama A, Loquai C, Mehnert JM, Hille D, Ebbinghaus S, Kang SP, Zhou W, Ribas A.

Eur J Cancer. 2016 Nov;67:46-54. doi: 10.1016/j.ejca.2016.07.018. Epub 2016 Sep 2.

26.

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.

Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, Joshua AM, Patnaik A, Hwu WJ, Weber JS, Gangadhar TC, Hersey P, Dronca R, Joseph RW, Zarour H, Chmielowski B, Lawrence DP, Algazi A, Rizvi NA, Hoffner B, Mateus C, Gergich K, Lindia JA, Giannotti M, Li XN, Ebbinghaus S, Kang SP, Robert C.

JAMA. 2016 Apr 19;315(15):1600-9. doi: 10.1001/jama.2016.4059. Erratum in: JAMA. 2016 Jun 14;315(22):2472.

PMID:
27092830
27.

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.

Hodi FS, Hwu WJ, Kefford R, Weber JS, Daud A, Hamid O, Patnaik A, Ribas A, Robert C, Gangadhar TC, Joshua AM, Hersey P, Dronca R, Joseph R, Hille D, Xue D, Li XN, Kang SP, Ebbinghaus S, Perrone A, Wolchok JD.

J Clin Oncol. 2016 May 1;34(13):1510-7. doi: 10.1200/JCO.2015.64.0391. Epub 2016 Mar 7.

28.

Yttrium Iron Garnet Thin Films with Very Low Damping Obtained by Recrystallization of Amorphous Material.

Hauser C, Richter T, Homonnay N, Eisenschmidt C, Qaid M, Deniz H, Hesse D, Sawicki M, Ebbinghaus SG, Schmidt G.

Sci Rep. 2016 Feb 10;6:20827. doi: 10.1038/srep20827.

29.

RNA Hairpin Folding in the Crowded Cell.

Gao M, Gnutt D, Orban A, Appel B, Righetti F, Winter R, Narberhaus F, Müller S, Ebbinghaus S.

Angew Chem Int Ed Engl. 2016 Feb 24;55(9):3224-8. doi: 10.1002/anie.201510847. Epub 2016 Feb 2.

30.

Simultaneous measurements of photocurrents and H2O2 evolution from solvent exposed photosystem 2 complexes.

Vöpel T, Ning Saw E, Hartmann V, Williams R, Müller F, Schuhmann W, Plumeré N, Nowaczyk M, Ebbinghaus S, Rögner M.

Biointerphases. 2015 Mar 22;11(1):019001. doi: 10.1116/1.4938090.

PMID:
26700470
31.

The macromolecular crowding effect--from in vitro into the cell.

Gnutt D, Ebbinghaus S.

Biol Chem. 2016 Jan;397(1):37-44. doi: 10.1515/hsz-2015-0161. Review.

PMID:
26351910
32.

Pembrolizumab.

Khoja L, Butler MO, Kang SP, Ebbinghaus S, Joshua AM.

J Immunother Cancer. 2015 Aug 18;3:36. doi: 10.1186/s40425-015-0078-9. eCollection 2015. Review.

33.

Synthesis, structure and properties of [Co(NCS)2(4-(4-chlorobenzyl)pyridine)2]n, that shows slow magnetic relaxations and a metamagnetic transition.

Werner J, Tomkowicz Z, Rams M, Ebbinghaus SG, Neumann T, Näther C.

Dalton Trans. 2015 Aug 21;44(31):14149-58. doi: 10.1039/c5dt01898f.

PMID:
26182402
34.

Defect properties of cobalt-doped hexagonal barium titanate ceramics.

Langhammer HT, Böttcher R, Müller T, Walther T, Ebbinghaus SG.

J Phys Condens Matter. 2015 Jul 29;27(29):295901. doi: 10.1088/0953-8984/27/29/295901. Epub 2015 Jul 8.

PMID:
26154400
35.

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.

Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, Cranmer LD, Blank CU, O'Day SJ, Ascierto PA, Salama AK, Margolin KA, Loquai C, Eigentler TK, Gangadhar TC, Carlino MS, Agarwala SS, Moschos SJ, Sosman JA, Goldinger SM, Shapira-Frommer R, Gonzalez R, Kirkwood JM, Wolchok JD, Eggermont A, Li XN, Zhou W, Zernhelt AM, Lis J, Ebbinghaus S, Kang SP, Daud A.

Lancet Oncol. 2015 Aug;16(8):908-18. doi: 10.1016/S1470-2045(15)00083-2. Epub 2015 Jun 23.

PMID:
26115796
36.

Pembrolizumab versus Ipilimumab in Advanced Melanoma.

Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A; KEYNOTE-006 investigators.

N Engl J Med. 2015 Jun 25;372(26):2521-32. doi: 10.1056/NEJMoa1503093. Epub 2015 Apr 19.

37.

Valence properties of Cu and Ru in titanium-substituted LnCu3Ru4O12+δ (Ln = La, Pr, Nd) investigated by XANES and TGA.

Riegg S, Reller A, Loidl A, Ebbinghaus SG.

Dalton Trans. 2015 Jun 21;44(23):10852-9. doi: 10.1039/c4dt03876b. Epub 2015 Mar 31.

PMID:
25824812
38.

Infrared laser triggered release of bioactive compounds from single hard shell microcapsules.

Vöpel T, Scholz R, Davico L, Gross M, Büning S, Kareth S, Weidner E, Ebbinghaus S.

Chem Commun (Camb). 2015 Apr 25;51(32):6913-6. doi: 10.1039/c4cc09745a. Epub 2015 Feb 9.

PMID:
25659363
39.

Excluded-volume effects in living cells.

Gnutt D, Gao M, Brylski O, Heyden M, Ebbinghaus S.

Angew Chem Int Ed Engl. 2015 Feb 16;54(8):2548-51. doi: 10.1002/anie.201409847. Epub 2014 Dec 29.

40.

Modulation of human IAPP fibrillation: cosolutes, crowders and chaperones.

Gao M, Estel K, Seeliger J, Friedrich RP, Dogan S, Wanker EE, Winter R, Ebbinghaus S.

Phys Chem Chem Phys. 2015 Apr 7;17(13):8338-48. doi: 10.1039/c4cp04682j. Epub 2014 Nov 19.

PMID:
25406896
41.

Combination of the mTOR inhibitor ridaforolimus and the anti-IGF1R monoclonal antibody dalotuzumab: preclinical characterization and phase I clinical trial.

Di Cosimo S, Sathyanarayanan S, Bendell JC, Cervantes A, Stein MN, Braña I, Roda D, Haines BB, Zhang T, Winter CG, Jha S, Xu Y, Frazier J, Klinghoffer RA, Leighton-Swayze A, Song Y, Ebbinghaus S, Baselga J.

Clin Cancer Res. 2015 Jan 1;21(1):49-59. doi: 10.1158/1078-0432.CCR-14-0940. Epub 2014 Oct 15.

42.

Lithiated sulfoxides: α-sulfinyl functionalized carbanions.

Ludwig G, Rüffer T, Hoppe A, Walther T, Lang H, Ebbinghaus SG, Steinborn D.

Dalton Trans. 2015 Mar 28;44(12):5323-30. doi: 10.1039/c4dt02238f.

PMID:
25300739
43.

Influence of the co-ligand on the magnetic and relaxation properties of layered cobalt(II) thiocyanato coordination polymers.

Wöhlert S, Tomkowicz Z, Rams M, Ebbinghaus SG, Fink L, Schmidt MU, Näther C.

Inorg Chem. 2014 Aug 18;53(16):8298-310. doi: 10.1021/ic500572p. Epub 2014 Jul 31.

PMID:
25080077
44.

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.

Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC, Patnaik A, Dronca R, Zarour H, Joseph RW, Boasberg P, Chmielowski B, Mateus C, Postow MA, Gergich K, Elassaiss-Schaap J, Li XN, Iannone R, Ebbinghaus SW, Kang SP, Daud A.

Lancet. 2014 Sep 20;384(9948):1109-17. doi: 10.1016/S0140-6736(14)60958-2. Epub 2014 Jul 15.

PMID:
25034862
45.

Protein stabilization by macromolecular crowding through enthalpy rather than entropy.

Senske M, Törk L, Born B, Havenith M, Herrmann C, Ebbinghaus S.

J Am Chem Soc. 2014 Jun 25;136(25):9036-41. doi: 10.1021/ja503205y. Epub 2014 Jun 16.

PMID:
24888734
46.

Structural and magnetic studies of a new Co(II) thiocyanato coordination polymer showing slow magnetic relaxations and a metamagnetic transition.

Wöhlert S, Fic T, Tomkowicz Z, Ebbinghaus SG, Rams M, Haase W, Näther C.

Inorg Chem. 2013 Nov 18;52(22):12947-57. doi: 10.1021/ic4012235. Epub 2013 Oct 30.

PMID:
24171470
47.

Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC).

Meulenbeld HJ, de Bono JS, Tagawa ST, Whang YE, Li X, Heath KH, Zandvliet AS, Ebbinghaus SW, Hudes GR, de Wit R.

Cancer Chemother Pharmacol. 2013 Oct;72(4):909-16. doi: 10.1007/s00280-013-2250-6. Epub 2013 Aug 7.

PMID:
23921574
48.

Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A.

N Engl J Med. 2013 Jul 11;369(2):134-44. doi: 10.1056/NEJMoa1305133. Epub 2013 Jun 2.

49.

Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy.

Demetri GD, Chawla SP, Ray-Coquard I, Le Cesne A, Staddon AP, Milhem MM, Penel N, Riedel RF, Bui-Nguyen B, Cranmer LD, Reichardt P, Bompas E, Alcindor T, Rushing D, Song Y, Lee RM, Ebbinghaus S, Eid JE, Loewy JW, Haluska FG, Dodion PF, Blay JY.

J Clin Oncol. 2013 Jul 1;31(19):2485-92. doi: 10.1200/JCO.2012.45.5766. Epub 2013 May 28.

PMID:
23715582
50.

A phase I trial of oral ridaforolimus (AP23573; MK-8669) in combination with bevacizumab for patients with advanced cancers.

Nemunaitis J, Hochster HS, Lustgarten S, Rhodes R, Ebbinghaus S, Turner CD, Dodion PF, Mita MM.

Clin Oncol (R Coll Radiol). 2013 Jun;25(6):336-42. doi: 10.1016/j.clon.2013.02.005. Epub 2013 Apr 21.

PMID:
23615181

Supplemental Content

Loading ...
Support Center